APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis.
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 225 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Study Start Date: November 2013
Actual Primary Completion Date: August 2017
Actual Study Completion Date: August 2017
Arms:
- Active Comparator: patisiran (ALN-TTR02)
- Placebo Comparator: Sterile Normal Saline (0.9% NaCl)
Category | Value |
---|---|
Date last updated at source | 2017-09-15 |
Study type(s) | Interventional |
Expected enrolment | 225 |
Study start date | 2013-11-01 |
Estimated primary completion date | 2017-08-01 |